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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder with a complex genetic
background, hampering identification of underlying genetic risk factors. We hypothesized that combining linkage analysis
and whole-exome sequencing (WES) in multi-generation pedigrees with multiple affected individuals can point toward
novel ADHD genes. Three families with multiple ADHD-affected members (Ntotal= 70) and apparent dominant inheritance
pattern were included in this study. Genotyping was performed in 37 family members, and WES was additionally carried out
in 10 of those. Linkage analysis was performed using multi-point analysis in Superlink Online SNP 1.1. From prioritized
linkage regions with a LOD score ≥ 2, a total of 24 genes harboring rare variants were selected. Those genes were taken
forward and were jointly analyzed in gene-set analyses of exome-chip data using the MAGMA software in an independent
sample of patients with persistent ADHD and healthy controls (N= 9365). The gene-set including all 24 genes together, and
particularly the gene-set from one of the three families (12 genes), were significantly associated with persistent ADHD in this
sample. Among the latter, gene-wide analysis for the AAED1 gene reached significance. A rare variant (rs151326868) within
AAED1 segregated with ADHD in one of the families. The analytic strategy followed here is an effective approach for
identifying novel ADHD risk genes. Additionally, this study suggests that both rare and more frequent variants in multiple
genes act together in contributing to ADHD risk, even in individual multi-case families.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
multifactorial neurodevelopmental disorder, character-
ized by age-inappropriate inattention, hyperactivity, and
increased impulsivity. ADHD is frequent in children, and
in up to 60% of the cases impairments persist into
adulthood [1]. ADHD presents a high risk for developing
co-morbid disorders, increasing the burden on social,
educational, and professional aspects of life [2, 3].
Family and twin studies showed that ADHD is highly
heritable, both in childhood and in adulthood, with
heritability estimates range between 70 and 90% [4–6].
Despite this considerable heritability, the identification
of risk genes has been challenging [3, 7], and one reason
for this could be the genetic complexity of the disease.
Identified candidate genes so far mainly belong to
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monoaminergic neurotransmitter pathways, especially
dopaminergic and serotonergic signaling [8–12]. Dif-
ferent (hypothesis-free) approaches, including genome-
wide linkage analyses and genome-wide association
studies (GWASs), have been performed in order to detect
additional genetic factors for ADHD. In line with the
‘common disease-common variant’ model, mostly com-
mon genetic factors have been investigated, which gen-
erally convey very small effect sizes [3]. However,
GWASs of ADHD are only just reaching sufficiently
large samples sizes to produce genome-wide significant
results. Linkage analysis, a method useful for identifi-
cation of genetic risk factors of larger effect size using
family data, has also contributed to the identification of
risk loci for ADHD. A meta-analysis of linkage studies
in ADHD reported a significant region in the distal part
of chromosome 16q [13]. Within this region, the CDH13
gene was repeatedly found among the top-findings in
GWASs [14]. In addition, linkage analysis in families
from a genetic isolate in combination with association
testing identified the ADGRL3/LPHN3 gene as an ADHD
risk factor [15, 16]. More evidence for involvement of
less frequent genetic variants with potentially larger
effect sizes comes e.g. from genome-wide studies of
copy number variants (CNVs) [17–21] and initial exome-
chip [22] and whole-exome sequencing (WES) work
[23, 24]. In addition, WES has been successful in iden-
tifying rare risk alleles for other neurodevelopmental/
psychiatric disorders, such as autism spectrum disorders
(ASDs) and schizophrenia (e.g. [25, 26]).
In this study, we explored whether a combination of
linkage analysis and WES in large multi-generational
pedigrees is a viable approach to gene-finding in ADHD.
We narrowed down the search area for rare variants by
linkage analysis in three multi-generation pedigrees with
multiple ADHD-affected members. Based on the WES
applied to subsets of family members, we selected rare
variants present in all (suggestive) linkage regions in each
family. In line with the polygenic nature of ADHD, in
which both common and rare genetic variants are likely to
contribute to disease etiology, we subsequently used the
extracted gene-sets to analyze the cumulative role of
common and rare variants in persistent ADHD in an
independent exome-chip data set (IMpACT consortium;
N= 9365 [22]).
Materials and methods
Study participants
Multigenerational pedigrees
The study included three multi-generational families with
multiple ADHD affected individuals (Ntotal= 70, NADHD=
41). The structure of the three families (Pedigree 1–3;
P1–P3) is summarized in Table 1 and shown in Supple-
mentary Figure 1. All families were of German origin and
were ascertained through affected children referred to the
outpatient clinic of the Department of Child and Adolescent
Psychiatry and Psychotherapy, University Hospital Würz-
burg, Germany. For the index-child, strict inclusion and
exclusion criteria were applied. Included index-children
were aged ≥6 years and met criteria for ADHD combined
subtype according to DSM-IV. Index-children had a birth
weight >2000 g and Intelligence Quotient (IQ) > 80, did not
show any neurological or severe somatic disorder, drug
abuse or ASDs, and did not receive psychotropic medica-
tion (except for stimulant medication for ADHD). Detailed
description of the diagnostic procedure for family members
was reported previously [27]. The study was approved by
the Ethics Committee of the Julius-Maximilians-University
of Würzburg. Written informed consent was obtained from
all participating individuals.
Exome-chip data set
The data set, which did not include members of the families
above, was genotyped on the Infinium Human CoreExome
chip (Illumina, San Diego, CA, USA) and comprised 1846
adults with persistent ADHD and 7519 controls recruited
from four different countries: Spain (615 cases and 932
controls), Norway (597 cases and 2598 controls), Germany
(340 cases and 2 286 controls), and The Netherlands (294
cases and 1703 controls). Part of the Dutch controls were
derived from the Nijmegen Biomedical Study (NBS, www.
nijmegenbiomedischestudie.nl), a population-based survey
conducted by the Departments of Epidemiology & Biosta-
tistics and Clinical Chemistry of the Radboud University
Medical Center [28]. Part of the Norwegian controls were
derived from The Nord-Trøndelag Health Study (The
HUNT study), a large population-based cohort [29]. Part of
Table 1 Summary of the
families included in this study
Family Total Affected Unaffected Unknown WES Genotyping
P1 11 9 1 1 5 7
P2 29 15 6 8 2 15
P3 30 17 8 5 3 15
WES whole-exome sequencing; genotyping indicates the number of family members with available genome-
wide genotyping data for linkage analyses
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the German controls were derived from the
Heinz–Nixdorf–Recall cohort, a large population-based
cohort [30]. Persistent adult ADHD was diagnosed
according to DSM-IV criteria. A detailed description of all
samples and (genotyping) procedures was recently pub-
lished [22], and a shortened version is included in the Sup-
plementary Methods. ADHD cases were of European
descent and were part of the International Multicenter per-
sistent ADHD Collaboration (IMpACT [31]). The study
was approved by the Ethics Committees of the respective
universities and/or hospitals. All participants signed
informed consent.
Single-nucleotide polymorphism (SNP) genotyping
and linkage analysis
Genome-wide SNP genotyping was performed on Affy-
metrix Genome-Wide Human SNP Array 6.0 (Affymetrix,
Santa Clara, CA, USA). Microarray quality control para-
meters and genotype calls were generated with Affymetrix
Genotyping Console v4.2.0.26 software (call rate > 0.99).
Individuals were excluded if their call rate was below 97%.
Genotyping data were filtered by removing SNPs with
minor allele frequency (MAF) < 5%, missing genotypes >
5%, Mendelian errors > 10% for variants, or deviations from
Hardy–Weinberg equilibrium (HWE, P ≤ 10−6). The
remaining 665,362 SNPs were pruned to reduce linkage
disequilibrium (LD) between markers using PLINK
v1.07 software (http://pngu.mgh.harvard.edu/purcell/plink/
[32]) with pairwise R2 > 0.01 in sliding windows of 50
SNPs, moving in intervals of five SNPs. In total, 10,842
autosomal SNPs were included in the linkage analyses.
Multi-point linkage analyses of genome-wide SNP data
were performed using Superlink Online SNP 1.1 [33],
which can handle large pedigrees. Through parametric
analysis, we computed logarithm of odds (LOD) scores
using groups of markers with a window size of 10 markers.
Based on the phenotypic characteristics of the pedigrees, a
dominant model was specified with an allele frequency of
0.01 and a penetrance value of 0.99. The significance level
was set at a LOD score of 3.3, but a score ≥2 was used to
select candidate regions for further analyses (Supplementary
Figure 2). The linked regions were bounded using 1 LOD-
score intervals upstream and downstream from the marker
with the highest LOD-score. Haplotypes of the regions of
interest were constructed by using the haplotyping tool of
Superlink Online SNP 1.133.
Whole-exome sequencing
For each family, two or more affected family members
were strategically selected for WES based on meiotic
distance and/or position in the pedigree (Table 1 and
Supplementary Figure 1). Genomic DNA was extracted
from blood samples according to standard protocols [27].
The exome was targeted by Agilent Sure Select Human
All Exon 50 Mb Target Enrichment kit (Agilent Tech-
nologies, Santa Clara, CA, USA) and sequenced by
single-end sequencing on the 5500xl SOLiDTM System
(Life Technologies, Carlsbad, CA, USA). High
quality reads were mapped to the hg19 reference genome
(UCSC genome browser) using the Lifescope
2.1 software (http://www.lifetechnologies.com/lifescope/)
with default parameters. In addition, the SOLiD Lifescope
Software v2.1 was used to call single-nucleotide variants
(SNVs) using the diBayes algorithm. Variant annotation
was done at the Department of Human Genetics of the
Radboud university medical center using a pipeline
developed in-house [34]. Variants were selected accord-
ing to the following criteria: (i) variants with ≥20 reads,
(ii) variants with a MAF < 1% in dbSNP (http://www.
ncbi.nlm.nih.gov/SNP/), and (iii) variants present in all
sequenced family members. Functional effects of variants
were predicted by three different softwares: SIFT [35],
PolyPhen-2 [36], and MutationTaster [37]. Conservation
of variants was estimated by PhyloP [38] and Grantham
score [39].
Gene-based and gene-set analyses in the exome-
chip data set
The cumulative effect of common and rare variants in
selected genes and gene-sets was tested using the inde-
pendent, recently published IMpACT exome-chip data set
(Supplementary Methods; [22]). Statistical analyses were
performed using the Multi-marker Analysis of GenoMic
Annotation (MAGMA) software package (version 1.02;
http://ctglab.nl/software/magma [40]) and the SNP-wide
mean model for gene-based association analysis (for
detailed description see Supplementary Methods). Impor-
tantly, all data sets (Spanish, Norwegian, German, and
Dutch) were analyzed individually, followed by meta-
analysis on the level of gene-based statistics. Fixed effects
were used to perform meta-analysis by using the square root
of the sample sizes as weights. An LD correction was
applied, based on the estimates of the 1000 genome phase 1
European ancestry samples [41]. Data were analyzed fol-
lowing a step-wise approach (see also Supplementary Fig-
ure 2): first, an overall gene-set was created, including all
genes identified by the approach described above (24
genes). We tested whether all genes together were jointly as
a gene-set associated with persistent ADHD. Post hoc to the
analysis of the overall gene-set, we also tested family-
specific gene-sets to localize the effect. Subsequently, we
performed a gene-based look-up of genes from family P2
(12 genes), and genes were considered gene-wide
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significant, if they reached the Bonferroni-corrected
threshold adjusted for the number of genes within the
gene-set (12 tests; P < 0.0042).
Gene Ontology enrichment analysis
To assess whether the 12 prioritized genes from family P2
converge on biological shared functions, we tested for
enrichment in Gene Ontology (GO) terms for biological
processes using FUMA [42]. Overrepresentation of bio-
logical functions of prioritized genes was tested for by
comparison with gene-sets obtained from the Molecular
Signature Database (MsigDB) v5.2 (i.e., GO gene sets),
using hypergeometric tests. The sets of background genes
were derived from 19,264 protein-coding genes.
Benjamini–Hochberg correction (FDR) was used for
multiple test correction method for gene-set enrichment
testing. Gene-set enrichments were considered significant
at an adjusted P-value level < 0.05.
Segregation analysis in family P2
To validate the presence of selected rare variants in the
two sequenced individuals and to allow segregation analysis,
all individuals of family P2 were genotyped for
chr9:99404124G>C (rs151326868) and chr8:124346225T>C
using PCR-based DNA sequencing. The locus of interest was
amplified by conventional PCR and sequenced by direct
Sanger sequencing (details and primer sequences are
available upon request). Data obtained for the two
variants were used to analyze the segregation with ADHD
diagnosis.
Table 2 List of candidate
regions and genes selected based
on the linkage analysis in each
family
Gene-set analysis
Family LR selected Genes with rare variants in WES Pself-
contained
Pcompetitive
P1 8:118608158–124649389 ----- 0.2838 0.4512
9:7754113–15568230 TYRP1, FREM1
9:97466973–102213749 -----
11:115218677–120365028 NXPE1,TMEM25, HYOU1, VPS11, ABCG4,
CCDC153
16:63079319–66386711 HSF4
16:81159781–83154022 DYNLRB2, PKD1L2, PLCG2, OSGIN1,
MBTPS1
P2 8:118608158–124649389 DEPTOR, ATAD2 0.0066 0.0042
9:7754113–15568230 PTPRD, TYRP1, FREM1
9:97466973–102213749 HSD17B3, AAED1, ANP32Ba, TBC1D2
10:56177098–58789387 PCDH15
10:64668048–65875491 -----
11:21968768–29134515 ANO3
11:115218677–120365028 BUD13, VPS11
13:106701406–109091885 -----
16:63079319–66386711 -----
P3 6:203878–460901 ----- 0.1368 0.1393
6:3446942–4470581 -----
9:97466973–102213749 -----
10:14311273–15844850 -----
10:64668048–65875491 -----
11:115218677–120365028 BUD13, TMEM25, VPS11
13:106701406–109091885 -----
16:63079319–66386711 CDH5
16:81159781–83154022 MBTPS1
Genes were included if they were present in the linkage region (LR; ± 1Mb) with LOD ≥ 2, to which the
family was contributing and if they harbored a rare variant (according to our selection criteria).
aNo variants were observed in the ANP32B gene in IMpACT exome-chip data. Gene-set-based association
analysis used meta-analytic exome-chip data from 9365 individuals (1846 ADHD patients and 7519
controls [22]).
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Results
Linkage analysis across three families with ADHD
The main aim of the linkage analyses was to provide an
additional filtering step for the WES data by narrowing down
the genomic regions of interest. Linkage analysis was per-
formed for each family individually, but also for all possible
combinations of the three families. Informative individuals
from each family were enrolled in the linkage study: nine
individuals from family P1, 19 individuals from family P2,
and 16 individuals from family P3 (Supplementary Figure 1).
A total of 13 linkage regions with LOD-score ≥ 2 on chro-
mosomes 6, 8, 9, 10, 11, 13, and 16 were identified (Sup-
plementary Table 1, Supplementary Figures 3 and 4), and all
were taken forward for subsequent analyses. Several sig-
nificantly linked regions were observed by analyzing families
together. The highest LOD scores (3.99 and 3.79) were
located on chromosome 16 in the analysis combining P1 and
P3 (Supplementary Table 1, Supplementary Figures 3 and 4).
In family P1, six linkage regions were selected (LOD-score ≥
2) for further analyses, but all of them needed the contribution
of at least one additional family to reach significance. In
family P2, nine linkage regions were identified, three of
which specific to this family, and in family P3, nine linkage
regions were identified of which five were specific to this
single family (all linkage regions with LOD-score ≥ 2; Table 2
and Supplementary Table 1).
Whole-exome sequencing analysis
A total of ten ADHD-affected family members were included
in WES: five from family P1 (ID1, ID2, ID4, ID5, and ID11),
two from family P2 (ID21 and ID26), and three from family
P3 (ID17, ID19, and ID20)) (Supplementary Figure 1). We
obtained an average of 5.46 billion bases of sequence per
individual and about 82.2% (~4.49 billion bp) of the total
bases mapped to the exomes, with a mean of 85-times cov-
erage (for WES sequencing statistics per individual see Sup-
plementary Table 1). Based on our selection criteria, the
average number of shared rare variants present in each family
was 1235 across the exome. Applying filtering based on the
identified linkage regions, a total of 20 variants were selected
from family P1, 13 variants from family P2, and five variants
from family P3 (Supplementary Table 3).
Association analyses and candidate gene
identification in an independent sample
All genes within linkage regions containing at least one of
the selected rare variants were included in a list of candidate
genes (Table 2). Gene-set analysis was performed based on
this list using exome-chip data from an independent sample
of 1846 adults with persistent ADHD and 7519 controls
[22]. Following testing of the overall gene-set (24 genes),
we also tested gene-sets resulted from each family sepa-
rately (Table 2). Meta-analysis of the individual exome-chip
samples showed significant association of the overall gene-
set in both self-contained and competitive tests (Pself-contained
= 0.0063 and Pcompetitive= 0.0103, Table 2). The significant
effect of the general gene-set was mainly driven by the
effect of genes selected based on the linkage analyses in
family P2 (Pself-contained= 0.0066 and Pcompetitive= 0.0042,
12 genes, Table 2), with additional minor contributions of
the gene-sets resulting from the linkage analysis in the other
two families (Supplementary Table 4). Focusing on indi-
vidual genes of the P2 gene-set, gene-based analysis
revealed that the AAED1 gene was significantly associated
with persistent ADHD (P= 0.0039). Another gene in this
gene set—ATAD2—yielded suggestive significance after
correction for multiple testing (P= 0.0072, Table 3). For
both genes, association was driven entirely by rare variants
(Supplementary Tables 5 and 6).
To assess whether the 12 prioritized genes of the family P2
gene-set converged on biological functions or pathways, we
tested for enrichment in GO terms (biological processes).
Four significantly enriched GO-terms were detected, includ-
ing ‘regulation of vesicle fusion’ (Padjusted= 0.0166) and
‘cell–cell adhesion via plasma membrane adhesion mole-
cules’ (Padjusted= 0.0328) (Supplementary Figure 5).
Single variant validation and familial segregation
analysis
Going back to the WES data of family P2, one rare mis-
sense variant was identified in both candidate genes
Table 3 Gene-based association results for the family P2 gene-set
using IMpACT exome-chip data of 9365 individuals (1846 ADHD
patients and 7519 controls; [22])
Gene N variants P
AAED1 5 0.0039a
ATAD2 5 0.0072
BUD13 11 0.0136
ANO3 9 0.1308
DEPTOR 6 0.2279
TYRP1 8 0.2824
TBC1D2 12 0.3181
VPS11 9 0.3258
PCDH15 27 0.3434
PTPRD 28 0.6350
HSD17B3 5 0.7097
FREM1 23 0.9460
aSignificant association after Bonferroni correction (12 tests, P <
0.00417).
Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome. . . 2051
(AAED1 and ATAD2) from the gene-based analysis.
The variant rs151326868, located in AAED1
(chr9:99404124G>C), was predicted to be deleterious in all
pathogenicity tests (Polyphen2, SIFT, and MutationTaster),
was highly conserved (PhyloP>2.7 and Grantham score
>80; Supplementary Table 7), and rare (MAF= 4.38 × 10−4
in the ExAC browser). The SNV chr8:124346225T>C in
ATAD2 was predicted to be deleterious only by Muta-
tionTaster, showed low conservation scores, and had very
low MAF in the ExAC browser (8.24 × 10−06; Supple-
mentary Table 7). The variant rs151326868 in AAED1 was
also present in the exome-chip data (exome-chip marker
exm764638; Supplementary Tables 5 and 6), the SNV
chr8:124346225T>C in ATAD2 was not.
Sanger sequencing of these two rare variants in AAED1
and ATAD2 in all members of family P2 for whom DNA
was available confirmed the presence of these variants in the
two sequenced individuals and allowed segregation analy-
sis. None of the healthy individuals carried either of the
variants, 93% of the affected individuals (14/15) carried at
least one of the two variants, and 60% of the affected
individuals (9/15) carried both variants (Fig. 1).
Discussion
In this study, we aimed to identify novel genetic risk factors
for ADHD by combining linkage analyses and WES in
multi-generation families. We predicted that through a
family-based approach, we would be able to limit genetic
heterogeneity, since rare variants with potentially higher
penetrance may cause the disorder in familial ADHD cases.
Linkage analyses revealed four genomic regions with a
LOD score ≥3.3 and 15 additional regions with a LOD score
≥2. Within these regions, we identified 38 rare variants
within 25 genes across the three families. All genes toge-
ther, and particularly the gene-set from family P2, were
significantly associated with persistent ADHD in the inde-
pendent exome-chip sample. Moreover, the AAED1 gene
reached gene-wide significance in that sample, and a rare
variant in AAED1 (rs151326868) segregated with ADHD in
family P2.
Different designs can be used for WES studies aiming at
identifying rare variants linked to complex diseases. In
schizophrenia [26] and ASDs [43–45], large sample sizes of
cases and controls have been used to find genes implicated
in disease through rare variants in multiple patients. For
ADHD, data sets have not yet reached the critical size to
allow for a genome-wide, hypothesis-free analysis of WES
data, but an initial study analyzed a pre-defined gene-set of
interest and found evidence for enrichment of rare variants
in cases [23]. A second approach, that has successfully been
applied in other neurodevelopmental disorders, especially in
ASDs [44, 46], is a trio-approach in sporadic patients and
their parents. In this approach, one is assuming that the
occurrence of the disorder in the patient is due to a de novo
mutation. In ADHD, this design may seem less promising
since the disorder does not reduce reproductive fitness as it
Fig. 1 Segregation analysis for rs151326868 (chr9:99404124G>C;
AAED1gene) and the SNV at chr8:124346225T>C (ATAD2gene) in
family P2. ADHD-affected individuals are depicted by black symbols,
unaffected family members are shown by white symbols and
individuals with unknown ADHD status are represented by a question
mark in the symbol. An asterisk beneath an individual indicates that
DNA was used for whole-exome sequencing analysis. Non-reference
alleles are depicted in bold.
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does in ASDs [47] and, therefore, sporadic cases are less
frequently described and familial aggregation of ADHD is
frequently observed [48]. However, recent evidence from
Swedish population registries suggests that ADHD risk is
strongly increased in the offspring of fathers older than 45
years [49], which seems to be linked to an age-related
increasing mutation rate in the paternal germline [50]. Our
own work also suggests that the cognitive profile of families
with only one affected individual differs from that of
families with more cases [51, 52], which may suggest that
the trio-design could also be successful in ADHD. The third
design, which we employed in the current study, is the
extended pedigree-based approach, in which one screens for
segregation of rare variants with disease across multiple
affected individuals. Knowledge on the etiology of ADHD
is, however, still limited, and therefore, ranking and prior-
itization of potential candidate genes is challenging. With
this in mind, our combined linkage and WES approach did
help to efficiently limit the list of potentially causative
variants in a data-driven way. Filtering WES variants by
linkage analysis has earlier been shown to be an effective
tool for prioritizing common and exome variants in exten-
ded families with ADHD [14] or ASD [53].
We extended the family-based approach by testing the
effects of observed genes carrying rare variants in an
independent, large sample of exome-chip data. Importantly,
most of the selected rare variants in the genes included in
the gene-set analysis of family P2 are exonic and non-
synonymous variants, so the overall result in the
case–control analyses would not be affected by more
stringent selection criteria for rare variants that are fre-
quently used in WES studies (e.g., being functionally
relevant). Specifically, the significant gene-based associa-
tion of AAED1 would remain. Utilizing this independent
sample, we showed that (some of the) identified genes may
be relevant to ADHD in the population, thereby general-
izing the findings from the single family. This approach also
enabled us to study the cumulative effect of rare and
common genetic variants in the identified candidate genes
for association with persistent ADHD, maximizing power to
find association by taking into account allelic heterogeneity
[8, 22].
Importantly, our work supports the notion that—despite
the apparent dominant segregation pattern - ADHD is not a
monogenic disorder in the pedigrees investigated. Linkage
analyses revealed several (suggestive) signals per family,
suggesting that several genes/loci may carry risk variants
for ADHD in each of those. Based on the linkage analyses,
we did not expect a single gene or single locus to be
associated with the clinical phenotype nor perfect co-
segregation pattern of the rare, non-reference allele with
ADHD in subsequent segregation analyses. A main con-
tributing factor to the observed patterns may be assortative
mating, which is common in ADHD [54] (and e.g. present
in family P1). Although we were quite liberal in selecting
regions for further analysis (through including suggestive
linkage signals), the observed pattern is similar to findings
in previous linkage studies of ADHD [13, 14] and other
neurodevelopmental disorders (e.g., for ASDs [53]).
The prioritized genes in the gene-set of family P2 con-
verged on the biological function of vesicle fusion, which
adds to the relevance of our findings, since the process of
vesicle fusion to plasma (e.g., synaptic) membrane is clo-
sely related to the mechanism of neurotransmitter release.
The AAED1 gene (coding for the AhpC/TSA Antioxidant
Enzyme Domain Containing 1 protein) was significantly
associated with persistent ADHD in the exome-chip sample,
and the rare variant in this gene (rs151326868; MAF for C-
allele in ExAC= 4.38 × 10−4) segregated with ADHD risk
in family P2. AAED1 strongly binds and interacts with the
Protein Kinase C-Alpha-Binding Protein (PICK1) [55].
PICK1 binds to the dopamine transporter (DAT), more
specifically to its carboxyl terminus, and is an important
regulator of DAT trafficking in presynaptic sites of dopa-
minergic neurons [56]. Additionally, a direct and functional
interaction between PICK1 and dopamine D3 receptors
(D3R) has been reported [57]. Furthermore, PICK1 has a
role in glutamate receptor regulation [58], and a recent
study revealed that a glutamate gene-set showed association
with the severity of hyperactivity/impulsivity in an ADHD
case-only sample [59]. In addition, adult Pick1 knockout
mice show several behavioral abnormalities, such as
hyperactivity and electrophysiological deficits in the pre-
frontal cortex [60]. With the prominent involvement of
dopamine regulation in ADHD, as e.g. the dopaminergic
system plays an important role in planning and initiation of
motor responses, activation, switching, reaction to novelty,
and reward processing [3], these molecular findings suggest
a link between genetic variation in AAED1, dopaminergic
and glutamatergic signaling, and ADHD risk. Thus, studies
of the AAED1 variant’s functional impact in carrier-derived
neurons of dopaminergic and glutamatergic specification,
which have been differentiated from induced pluripotent
stem cells (iPSCs), are currently being conducted (E. Svirin
& K.P. Lesch, unpublished results).
Our combined approach of linkage and WES also iden-
tified a rare genetic variant in the ATAD2 gene, coding for
the ATPase family AAA domain-containing protein 2, and
gene-based analysis of this gene revealed suggestive asso-
ciation with persistent ADHD. However, a neuronal func-
tion of this gene has not been described yet.
The findings described here need to be interpreted in
light of several strengths and limitations. Although we
considered only three families, we identified AAED1 as a
novel ADHD candidate gene, showing that combining
linkage analysis and WES can be an efficient strategy to
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prioritize ADHD-associated genes/variants. In contrast to
previous studies focusing on pre-defined gene-sets [23, 61],
we performed an exome-wide search for rare variants.
Additionally, we validated the association of the newly
identified ADHD risk genes in an independent sample.
However, two main types of genetic variation, which may
have helped us to find contributing genes in families P1 and
P3, remained unstudied. Firstly, genetic variation located in
intronic and intergenic regions may be discovered by using
whole-genome sequencing approaches. Alternatively,
common variants in regulatory regions close to the genes of
interest may be imputed and then included in association
analyses. Since we know from studies in other psychiatric
disorders that many risk variants are located within reg-
ulatory regions [62], genetic variation in those regions
probably also contributes to the genetic architecture of
ADHD. Secondly, CNVs could play a role in the etiology
of ADHD, since prior studies have noted an enrichment of
large CNVs in ADHD cases [17, 20, 63, 64], particularly in
genes related to neurodevelopment [21]. Moreover, future
studies may aim to integrate data from both rare variants
and the common polygenic load in those families, in order
to obtain a more complete picture on the genetic archi-
tecture of ADHD in the individual families.
In conclusion, we provide evidence for the role of rare
variants in protein-coding genes in the etiology of ADHD.
Our data adds to the notion that less frequent variants
provide an additional source of relevant genetic risk factors,
which received little attention in ADHD genetics so far.
Moreover, we show that genes harboring rare genetic var-
iants in individual families are associated with persistent
ADHD in an independent sample. Therefore, this study
suggests that the combination of linkage analyses and WES
provides a practical approach for gene identification in
genetically complex neurodevelopmental disorders, such as
ADHD.
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